文献速递炎症性肠病消化内镜

生物制剂诱导黏膜愈合在近端与远端小肠克罗恩病中地形学上相当

Induction of mucosal healing by biologics is topographically comparable in proximal and distal small bowel Crohn's disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-10-05

该研究汇总三项前瞻性队列,用小肠胶囊内镜评估生物制剂治疗克罗恩病近端与远端小肠黏膜炎症的变化。结果显示近端和远端小肠黏膜炎症均显著下降,且两段黏膜愈合程度相当。

要点

  • 生物制剂治疗可使近端和远端小肠克罗恩病黏膜炎症均显著改善。
  • 近端与远端小肠的黏膜愈合程度在诱导结束时和1年时均相当。
  • 使用更高炎症阈值时,两段小肠黏膜炎症也均显著下降。

核心结论

  • 生物制剂治疗与近端和远端小肠克罗恩病黏膜炎症的地形学相当改善相关。

研究设计与样本

  • 汇总三项前瞻性队列,纳入开始或优化生物制剂治疗的患者,在基线、诱导结束(14-26周)和1年时行小肠胶囊内镜评估。

主要发现

  • 近端小肠炎症率从基线63%降至诱导结束44%(p=0.001)和1年41%(p=0.003)。
  • 远端小肠炎症率从基线95%降至诱导结束78%(p=0.001)和1年71%(p<0.001)。
  • 诱导结束时近端与远端黏膜愈合程度相当(RD 7%,95% CI -9%至22%,p=0.391)。
  • 1年时近端与远端黏膜愈合程度相当(RD 0%,95% CI -17%至17%,p=1.000)。
  • 采用更高炎症阈值(LS≥350)时,近端和远端小肠黏膜炎症均显著下降。

关键数值与推荐

  • 黏膜炎症定义为Lewis评分(LS)≥135。
  • 小肠前两个三分位定义为近端小肠,第三个三分位定义为远端小肠。
  • 近端炎症定义为两个近端三分位中任一受累。

临床怎么用

  • 生物制剂治疗可同时改善近端和远端小肠克罗恩病黏膜炎症,支持其全局性黏膜愈合作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Proximal small bowel (SB) involvement is associated with worse outcomes in Crohn's disease (CD). We aimed to compare biologic response between proximal and distal SB segments using video capsule endoscopy (VCE) to assess small intestinal topography of inflammation. METHODS: Pooled analysis of three prospective cohorts including patients initiating or undergoing optimization of biologic therapy, who were evaluated with SB-VCE at baseline, end-of-induction (14-26 weeks), and 1-year. Mucosal inflammation was defined as Lewis score (LS)≥135. The first two SB tertiles were classified as proximal SB and the third as distal SB. Proximal inflammation was defined by involvement of either of the two proximal tertiles. Generalized estimating equations accounted for within-patient correlation, adjusting for segment, timepoint, biologic class, and disease phenotype. RESULTS: Ninety-nine patients received biologics (53-anti-TNF, 43-vedolizumab, 3-ustekinumab). 82 completed end-of-induction and 59 completed 1-year assessments. The rate of proximal SB inflammation decreased from 63% at baseline to 44% at the end-of-induction (p=0.001) and 41% at 1-year (p=0.003), while distal inflammation declined from 95% to 78% (p=0.001) and 71% (p<0.001), respectively. There was comparable degree of mucosal healing between proximal and distal segments at the end-of-induction (RD 7%, 95% CI -9% to 22%, p=0.391) and 1-year (RD 0%, 95% CI -17% to 17%, p=1.000). Using a higher inflammatory threshold (LS≥350), mucosal inflammation significantly decreased in both proximal (baseline: 38%, vs. end-of-induction: 16% [p<0.01] and 1-year: 19% [p=0.02]) and distal SB segments (baseline: 76% vs end-of-induction: 35% [p<0.01] and 1-year: 19% [p<0.01]). CONCLUSION: Biologic therapy is associated with topographically comparable improvement in mucosal inflammation across proximal and distal SB segments.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Ukashi O, Kopylov U, Ungar B, et al. Induction of mucosal healing by biologics is topographically comparable in proximal and distal small bowel Crohn's disease. Clin Gastroenterol Hepatol. 2026. PMID: 42833429. doi:10.1016/j.cgh.2026.09.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。